Abstract:Introduction: There is no established and useful tumor biomarker to evaluate treatment response and predict early locoregional and distant metastatic relapse in head and neck squamous cell carcinoma (HNSCC). Circulating tumor DNA (ctDNA) has a potential for detecting minimal residual diseases (MRDs). However, the absence of specific hotspot mutations in most HNSCCs makes ctDNA-based studies difficult in HNSCC. As a novel biomarker, we investigated whether individualized ctDNA analysis could help monitor and predict treatment response and relapse in HNSCC. Methods: Thirty-two HNSCC patients were enrolled in this study. Twenty-two patients received radical resection and 10 patients were received radical irradiation as initial curative treatment. We collected tumor tissues and paired PBMCs (peripheral blood mononuclear cells) before treatment. Furthermore, we collected serial plasma samples for ctDNA analysis. To identify tumor specific individualized mutation, we isolated DNA from tumor tissue and PBMC and performed mutation analysis using custom SCC panel with frequent altered 31 genes (all exon coverage). We defined tumor-specific mutated genes per patient with variant allele frequency (VAF) >10 % and total coverage >100 as ctDNA candidate genes and performed ctDNA analysis using dPCR. We generated mutation specific primer-probe for droplet digital PCR (ddPCR), quantified the amount of ctDNA in plasma and compared ctDNA level with clinical data. Results: For mutation analysis, most frequent mutated gene was TP53 (21/32, 65.6%). Longitudinal ctDNA was monitored in a total of 24 cases. In 13 cases, ctDNA tested positive again or did not test negative, and all 13 cases had a residual tumor or relapsed after initial treatment. In 11 cases, after initial treatment, ctDNA remained negative and patients were alive without recurrence. Our cohort included 6 patients in whom it was possible to monitor ctDNA during chemotherapy in recurrent metastatic HNSCC cases. ctDNA alterations correlated well with clinical treatment response in four cases, but not in two cases. Patients who remained negative for ctDNA during follow-up after initial treatment (n=11) had a significantly better prognosis than those who reverted to ctDNA positivity (n=13, P < 0.0001). Conclusion: Custom SCC panel is useful to detect more tumor specific mutation in HNSCC patients. Detection of ctDNA using next generation sequencing and digital PCR is promising strategy capable of monitoring in HNSCC patients. However, this method is not useful in all HNSCC, and there is room for improvement in the selection of ctDNA candidate genes. Citation Format: Ryunosuke Kogo, Tomomi Manako, Takashi Nakagawa. Personalized longitudinal ctDNA monitoring is useful for biomarker in head and neck squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2419.

The Diagnostic Value and Prospects of Gene Mutations in Circulating Tumor DNA for Head and Neck Cancer Monitoring

The Implications of Gene Mutations in Salivary DNA for Noninvasive Diagnosis of Head and Neck Cancer with a Focus on Oral Cancer.

Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma

Detection Of Circulating Tumor Dna In Patients With Advanced Non-Small Cell Lung Cancer

The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer.

Abstract 2419: Personalized longitudinal ctDNA monitoring is useful for biomarker in head and neck squamous cell carcinoma

Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma

Does circulating tumor DNA apply as a reliable biomarker for the diagnosis and prognosis of head and neck squamous cell carcinoma?

The feasibility of using mutation detection in ctDNA to assess tumor dynamics

Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis

Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next‐Generation Sequencing With Insufficient Tumor Samples

Personalized circulating tumor DNA for monitoring disease status in head and neck squamous cell carcinoma

"Liquid biopsy"-ctDNA detection with great potential and challenges.

The Diagnostic and Prognostic Usage of Circulating Tumor DNA in Operable Hepatocellular Carcinoma.

The Role of ctDNA and Liquid Biopsy in the Diagnosis and Monitoring of Head and Neck Cancer: Towards Precision Medicine

Circulating Tumor DNA As an Emerging Liquid Biopsy Biomarker for Early Diagnosis and Therapeutic Monitoring in Hepatocellular Carcinoma

Efficient mutation screening for cervical cancers from circulating tumor DNA in blood

Circulating tumour DNA detects somatic variants contributing to spatial and temporal intra-tumoural heterogeneity in head and neck squamous cell carcinoma

Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients

Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques